Research programme: gene editing therapeutics - Metagenomi
Latest Information Update: 22 Aug 2024
At a glance
- Originator Metagenomi
- Developer Metagenomi; Moderna Therapeutics
- Class Gene therapies; Urologics
- Mechanism of Action Gene transference; Glycolate oxidase expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Primary hyperoxaluria type 1
Highest Development Phases
- Research Primary hyperoxaluria type 1